Drug intelligence / Profile preview

ARTX-405

Development stage: Preclinical
Lead developer: Artus Tx
Modality: Small Molecules
Administration: Oral

Overview

ARTX-405 is an orally administered small molecule developmental lead candidate being developed by Artus Tx (Artus Therapeutics). It is designed to treat gastrointestinal, neurological, and metabolic disorders by addressing gut barrier dysfunction. The drug's mechanism of action involves enhancing both epithelial and endothelial barrier integrity, which facilitates mucosal healing. Unlike many existing anti-inflammatory treatments, ARTX-405 aims to restore barrier function without compromising the immune system. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on ARTX-405.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARTX-405.

Explore the full profile